Why is Parmax Pharma falling/rising?

As of 17-Jul, Parmax Pharma Ltd is experiencing a decline in its stock price, currently at 40.06, which reflects a decrease of 0.58 or 1.43%. The stock has underperformed its sector by 1.85% today and has been on a consecutive downward trend for the last two days, resulting in a total return of -4.62% over the past year. Despite reporting positive net sales growth of 98.75% in the last six months and achieving positive results for the last three consecutive quarters, the company is facing significant challenges. It has a negative book value and weak long-term fundamental strength, with poor growth rates in net sales and operating profit over the past five years. Additionally, the stock's liquidity appears to be decreasing, as evidenced by a 29.81% drop in delivery volume compared to the five-day average.
In the broader market context, Parmax Pharma's short-term performance has been slightly better than the benchmark, with a 1-week return of -1.09% compared to the Sensex's -1.12%. However, the stock has underperformed the benchmark over longer periods, including a -9.47% return year-to-date versus the Sensex's +5.27%. This underperformance, coupled with the company's weak ability to service its debt and negative operating profits, contributes to a perception of risk among investors, which may be influencing the stock's current downward trajectory.